Brennan, Frank R.

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

Brennan, F. R., Morton, L. D., Spindeldreher, S., Kiessling, A., Allenspach, R., Hey, A., Müller, P., Frings, W., & Sims, J. (2010) · mAbs

Immunotoxicology and immune responsesMonoclonal and Polyclonal Antibodies Research

Cited by 250

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

Kiessling, P., Lledo-Garcia, R., Watanabe, S., Langdon, G., Tran, D., Bari, M., Christodoulou, L., Jones, E., Price, G., Smith, B., et al. (2017) · Science Translational Medicine

Monoclonal and Polyclonal Antibodies ResearchImmunodeficiency and Autoimmune Disorders

Cited by 211

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration

Smith, B., Kiessling, A., Lledo-Garcia, R., Dixon, K. L., Christodoulou, L., Catley, M. C., Atherfold, P., D’Hooghe, L. E., Finney, H., Greenslade, K., et al. (2018) · mAbs

Monoclonal and Polyclonal Antibodies ResearchSystemic Lupus Erythematosus Research

Cited by 117

Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment

Brennan, F. R., Cavagnaro, J., McKeever, K., Ryan, P. C., Schutten, M. M., Vahle, J., Weinbauer, G. F., Marrer-Berger, E., & Black, L. E. (2018) · mAbs

Monoclonal and Polyclonal Antibodies ResearchAnimal testing and alternatives

Cited by 70